Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.

@article{Kurabayashi2008SuperiorBO,
  title={Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.},
  author={Masahiko Kurabayashi and Tsutomu Yamazaki},
  journal={Journal of atherosclerosis and thrombosis},
  year={2008},
  volume={15 6},
  pages={314-23}
}
AIM There have been few comparisons between rosuvastatin and other statins in Japanese patients. This open-label, randomized, parallel-group comparative study was performed to compare the efficacy and safety of rosuvastatin (5 mg) and atorvastatin (10 mg) once daily in Japanese patients with hypercholesterolemia. METHODS Patients with hypercholesterolemia who had received atorvastatin (10 mg/day) for at least 4 weeks and were in category B3, B4, or C according to the Japan Atherosclerosis… CONTINUE READING